Cargando…
Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial
Probiotics play a key role in maintaining the health of the female reproductive tract, representing a promising alternative to safeguard or restore the homeostasis of the vaginal microbiota. The present randomized double-blind placebo-controlled study was performed to evaluate the ability of the pot...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869686/ https://www.ncbi.nlm.nih.gov/pubmed/36700035 http://dx.doi.org/10.3389/fsurg.2022.1075612 |
_version_ | 1784876819945619456 |
---|---|
author | Rapisarda, Agnese Maria Chiara Pino, Alessandra Grimaldi, Raffaela Luisa Caggia, Cinzia Randazzo, Cinzia Lucia Cianci, Antonio |
author_facet | Rapisarda, Agnese Maria Chiara Pino, Alessandra Grimaldi, Raffaela Luisa Caggia, Cinzia Randazzo, Cinzia Lucia Cianci, Antonio |
author_sort | Rapisarda, Agnese Maria Chiara |
collection | PubMed |
description | Probiotics play a key role in maintaining the health of the female reproductive tract, representing a promising alternative to safeguard or restore the homeostasis of the vaginal microbiota. The present randomized double-blind placebo-controlled study was performed to evaluate the ability of the potential probiotic Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated, to balance the vaginal microbiota of women with vaginal dysbiosis. Sixty women, with signs and symptoms of vaginal dysbiosis, were recruited and randomly allocated to receive oral capsules containing the L. rhamnosus CA15 (DSM 33960) strain at 1.0 × 10(10) colony-forming units or placebo once daily for 10 days. Clinical and microbiological parameters were evaluated in three scheduled appointments: at baseline (T0), 10 days after the start of the treatment (T1), and 30 days after the end of the treatment (T2). In addition, the quality of life, through the WHO quality of life assessment questionnaire, was assessed at baseline (T0) and 30 days after the end of the treatment (T2). The probiotic was well tolerated and no side effects were reported. The oral consumption of the potential probiotic L. rhamnosus CA15 (DSM 33960) strain determined a significant improvement of both clinical signs and symptoms not only 10 days after the start of the treatment (T1) but also 30 days after the end of the treatment (T2). A significant reduction of potential pathogens and a concomitant increase of lactobacilli was revealed, by microbial count, at both T1 and T2 sampling times. In addition, the enhancement of the perceived physical health, social relations, and environment was reported. Differently, in placebo group clinical and microbiological parameters as well as quality of life remained almost unchanged. The potential probiotic L. rhamnosus CA15 (DSM 33960) strain could be a safe and effective approach to restore and maintain a balanced vaginal microbiota. |
format | Online Article Text |
id | pubmed-9869686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98696862023-01-24 Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial Rapisarda, Agnese Maria Chiara Pino, Alessandra Grimaldi, Raffaela Luisa Caggia, Cinzia Randazzo, Cinzia Lucia Cianci, Antonio Front Surg Surgery Probiotics play a key role in maintaining the health of the female reproductive tract, representing a promising alternative to safeguard or restore the homeostasis of the vaginal microbiota. The present randomized double-blind placebo-controlled study was performed to evaluate the ability of the potential probiotic Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated, to balance the vaginal microbiota of women with vaginal dysbiosis. Sixty women, with signs and symptoms of vaginal dysbiosis, were recruited and randomly allocated to receive oral capsules containing the L. rhamnosus CA15 (DSM 33960) strain at 1.0 × 10(10) colony-forming units or placebo once daily for 10 days. Clinical and microbiological parameters were evaluated in three scheduled appointments: at baseline (T0), 10 days after the start of the treatment (T1), and 30 days after the end of the treatment (T2). In addition, the quality of life, through the WHO quality of life assessment questionnaire, was assessed at baseline (T0) and 30 days after the end of the treatment (T2). The probiotic was well tolerated and no side effects were reported. The oral consumption of the potential probiotic L. rhamnosus CA15 (DSM 33960) strain determined a significant improvement of both clinical signs and symptoms not only 10 days after the start of the treatment (T1) but also 30 days after the end of the treatment (T2). A significant reduction of potential pathogens and a concomitant increase of lactobacilli was revealed, by microbial count, at both T1 and T2 sampling times. In addition, the enhancement of the perceived physical health, social relations, and environment was reported. Differently, in placebo group clinical and microbiological parameters as well as quality of life remained almost unchanged. The potential probiotic L. rhamnosus CA15 (DSM 33960) strain could be a safe and effective approach to restore and maintain a balanced vaginal microbiota. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9869686/ /pubmed/36700035 http://dx.doi.org/10.3389/fsurg.2022.1075612 Text en © 2023 Rapisarda, Pino, Grimaldi, Caggia, Randazzo and Cianci. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Surgery Rapisarda, Agnese Maria Chiara Pino, Alessandra Grimaldi, Raffaela Luisa Caggia, Cinzia Randazzo, Cinzia Lucia Cianci, Antonio Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial |
title | Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial |
title_full | Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial |
title_fullStr | Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial |
title_full_unstemmed | Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial |
title_short | Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial |
title_sort | lacticaseibacillus rhamnosus ca15 (dsm 33960) strain as a new driver in restoring the normal vaginal microbiota: a randomized, double-blind, placebo-controlled clinical trial |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869686/ https://www.ncbi.nlm.nih.gov/pubmed/36700035 http://dx.doi.org/10.3389/fsurg.2022.1075612 |
work_keys_str_mv | AT rapisardaagnesemariachiara lacticaseibacillusrhamnosusca15dsm33960strainasanewdriverinrestoringthenormalvaginalmicrobiotaarandomizeddoubleblindplacebocontrolledclinicaltrial AT pinoalessandra lacticaseibacillusrhamnosusca15dsm33960strainasanewdriverinrestoringthenormalvaginalmicrobiotaarandomizeddoubleblindplacebocontrolledclinicaltrial AT grimaldiraffaelaluisa lacticaseibacillusrhamnosusca15dsm33960strainasanewdriverinrestoringthenormalvaginalmicrobiotaarandomizeddoubleblindplacebocontrolledclinicaltrial AT caggiacinzia lacticaseibacillusrhamnosusca15dsm33960strainasanewdriverinrestoringthenormalvaginalmicrobiotaarandomizeddoubleblindplacebocontrolledclinicaltrial AT randazzocinzialucia lacticaseibacillusrhamnosusca15dsm33960strainasanewdriverinrestoringthenormalvaginalmicrobiotaarandomizeddoubleblindplacebocontrolledclinicaltrial AT cianciantonio lacticaseibacillusrhamnosusca15dsm33960strainasanewdriverinrestoringthenormalvaginalmicrobiotaarandomizeddoubleblindplacebocontrolledclinicaltrial |